---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-25-004421"
form_type: "8-K"
ticker: "PHIO"
cik: "0001533040"
company_name: "Phio Pharmaceuticals Corp."
filed_at: "2025-06-12T23:59:59+00:00"
generated_at: "2026-05-19T10:37:48.324520+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Phio Pharmaceuticals appoints Lisa Carson as CFO/PAO; Infarinato shifts to VP Strategic Development

## Summary
- Lisa Carson named VP Finance and Administration and designated principal financial and accounting officer, effective June 6, 2025.
- Robert Infarinato ceased as PFO/PAO, appointed VP Strategic Development effective June 9 to focus on INTASYL portfolio business development.
- Carson's compensation: $290k base salary, up to 30% annual bonus, $25k sign-on stipend; at-will employment.
- Company announces strategic initiative to raise awareness of INTASYL siRNA portfolio (~30 compounds); positive interim Phase 1b results for PH-762 in skin cancer.

## SEC filing metadata
- accession: 0001683168-25-004421
- form_type: 8-K
- ticker: PHIO
- cik: 0001533040
- company_name: Phio Pharmaceuticals Corp.
- filed_at: 2025-06-12T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1533040/000168316825004421/0001683168-25-004421-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1533040/000168316825004421/phio_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-25-004421
- JSON: https://secwatch.observer/filing/0001683168-25-004421.json
- Plain text: https://secwatch.observer/filing/0001683168-25-004421.txt

## Key facts
- Executive change
  Robert Infarinato was appointed as VP, Strategic Development at Phio Pharmaceuticals Corp..
  - Action: appointed
  - Role: VP, Strategic Development
  source text: Also effective June 6, 2025, Mr. Infarinato, who was previously the Company’s Chief Financial Officer, now serves as VP, Strategic Development of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1533040/000168316825004421/0001683168-25-004421-index.htm
- Executive change
  Lisa Carson was appointed as VP, Finance and Administration at Phio Pharmaceuticals Corp..
  - Action: designated
  - Role: VP, Finance and Administration
  source text: designated Lisa Carson, VP, Finance and Administration of the Company, as the Company’s principal financial officer and principal accounting officer, effective as of June 6, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1533040/000168316825004421/0001683168-25-004421-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.